Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Tamsulosin: Pipeline™ Selector' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Tamsulosin Pipeline Developer |
Ongoing | £2925 | 100 % |
|
Tamsulosin: Core Country Coverage Pipeline Selector |
Ongoing | £260 | 96 % |
|
Tamsulosin: Extended Country Coverage Pipeline Selector |
Ongoing | £610 | 96 % |
|
Flomax Case Study Evolving Disease State Awareness to Succeed with New Method of Action |
July 2008 | £2110 | 50 % |
|
Boehringer Ingelheim: Pipeline, Products, Performance, Potential |
April 2008 | £595 | 35 % |
|
Boehringer Ingelheim Pipeline ,Products ,Performance ,Potential |
November 2008 | £595 | 35 % |
|
Astellas Pipeline Products Performance Potential |
June 2008 | £595 | 22.75 % |
|
Pipeline Insight: Benign Prostatic Hyperplasia - Novel therapeutics and reformulations will drive market growth |
April 2009 | £6000 | 22.75 % |
|
Opportunities and Challenges for Generic Drugs in the UK 2007 |
June 2007 | £795 | 12.6 % |
|
Teva Pharmaceutical Industries Generics Company Intelligence Report |
June 2008 | £195 | 12.25 % |
|
Teva Generics Company Intelligence Report Company Intelligence Report |
March 2009 | £195 | 10.5 % |
|
Generic Competition, 2007–11 The impact of patent expiries on sales of major drugs |
February 2007 | £1375 | 8.05 % |
|
Handbook of Pharmaceutical Manufacturing Formulations - Vol 2 of 6 Uncompressed Solid Products |
April 2007 | £195 | 6.65 % |
|
World Generic Market Report 2009 |
January 2009 | £595 | 2.8 % |
